OBJECTIVES
We explore how broader aspects of a treatment's value and the impact of the condition on patients not captured by routine health technology assessment (HTA) methods using clinical and economic evidence, defined as "other considerations," may influence HTA processes in different settings.
METHODS
Countries included were England, Scotland, Sweden, and France. Data sources were the pu...